Lilly's Imlunestrant, an Oral Serd, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio® (Abemaciclib) in Patients With Er+, Her2- Advanced Breast Cancer
Lilly的Imlunestrant,一种口服选择性雌激素受体降解剂,显著改善了ER+、HER2-晚期乳腺癌患者在单药治疗和与Verzenio®(阿贝马唑)联合治疗中的无进展生存期。